Originally published in AHLA Health Law Weekly, March 27, 2026.
By Michelle Carroll
Predictive analytics are increasingly shaping discovery, expert testimony, and regulatory scrutiny in post-acute litigation. As artificial intelligence (AI)-generated alerts become visible in clinical records, courts are beginning to confront how these systems intersect with Rule 702 admissibility standards and governance obligations.
AI as Litigation Evidence
AI is no longer just a clinical tool in long term care—it is evidence. Predictive systems now generate timestamped alerts for fall risk, pressure injury escalation, early deterioration, medication interactions, and staffing acuity. When adverse events occur, those alerts enter discovery, shape expert analysis, and frame liability narratives.
The legal standard of care has not changed. The evidentiary landscape has. AI does not create new duties. It creates visibility. In litigation, visibility reshapes scrutiny.
As courts apply Federal Rule of Evidence 702 and parallel state admissibility standards to AI-influenced cases, the central question is no longer whether predictive systems are innovative. It is whether their use was governed, reconciled, and documented coherently. Structure—not software—determines admissibility posture.
AI in Long Term Care: From Clinical Tool to Litigation Artifact
Long-term care facilities increasingly deploy predictive analytics to monitor:
- Fall vulnerability
- Pressure injury risk
- Early physiologic deterioration
- Polypharmacy exposure
- Staffing acuity alignment
These systems aggregate well-recognized geriatric risk variables. They do not create new clinical categories; rather, they quantify vulnerability. What has changed is not the science of risk. It is the documentation of it.
Predictive systems generate:
- Timestamped alerts
- Escalation trends
- Override logs
- Audit trails
When adverse events occur, those artifacts frequently become central in discovery and expert review.
The litigation reframing often appears deceptively simple:
Alert → Event → Liability
Negligence doctrine, however, remains anchored in reasonable care under the circumstances[1]—not technological perfection.
Rule 702 and the Reliability-Application Divide
AI does not appear in court as software. It appears through expert testimony. Under Federal Rule of Evidence 702, expert testimony must be based on sufficient facts or data, reflect reliable principles and methods, and demonstrate reliable application of those principles to the facts of the case.[2] Trial courts serve as gatekeepers of that reliability, as articulated in Daubert v. Merrell Dow Pharmaceuticals, Inc.[3] and extended to technical and specialized knowledge in Kumho Tire Co. v. Carmichael.[4]
In AI-influenced long term care cases, admissibility risk rarely stems from algorithmic novelty. Most predictive systems rely on established geriatric risk indicators. The vulnerability arises elsewhere: in the translation from alert to conclusion.
Courts scrutinize whether:
- Alerts were acknowledged and reconciled;
- Override decisions were documented with articulated reasoning;
- Care plans reflected reassessment;
- Expert testimony converts probability into inevitability.
A validated predictive system does not insulate an institution from evidentiary challenge. Nor does the mere presence of an alert establish breach. The Rule 702 inquiry centers on coherence—whether the reasoning process connecting data, clinical response, and expert opinion is logically and reliably explained.[5]
Where documentation is fragmented or inferential steps are compressed, exclusion risk increases. As the Supreme Court cautioned in General Electric Co. v. Joiner, courts may reject expert opinions that make an excessive analytical leap between data and conclusion.[6] Rule 702 does not evaluate technological sophistication. It evaluates disciplined reasoning.
Daubert vs. Frye: Why Jurisdiction Matters
In jurisdictions applying the Daubert standard, courts evaluate reliability through flexible, non-exclusive factors.[7] In jurisdictions adhering to Frye v. United States,[8] admissibility turns on whether the methodology is generally accepted within the relevant scientific community.
Most predictive long term care systems rely on established clinical indicators rather than novel scientific theory. As a result, exclusion risk typically centers less on general acceptance and more on documentation discipline and application clarity.
Counsel must assess venue early, as evidentiary posture directly affects motion strategy, mediation leverage, and expert preparation.
The Analytical Gap: When Probability Becomes Certainty
In General Electric Co. v. Joiner, the Supreme Court cautioned against excessive inferential leaps between data and expert conclusions.
AI-involved long term care cases frequently risk analytical compression:
Elevated fall risk → therefore the fall was preventable.
Sepsis alert → therefore deterioration was negligently ignored.
Predictive systems estimate probability within frail populations. They do not establish inevitability. Institutions reduce this vulnerability by expanding chronology:
Alert → Reassessment → Monitoring → Clinical Course → Outcome.
Timeline expansion restores clinical complexity and reinforces the advisory nature of predictive tools.
Documentation Architecture as Litigation Stabilizer
In AI-influenced long term care cases, documentation frequently determines admissibility posture. Courts do not require perfect outcomes. They require coherent reasoning consistent with reasonable care.[9]
Structured reconciliation entries should demonstrate:
- Alert acknowledgment;
- Clinical reassessment;
- Monitoring or intervention;
- Override rationale;
- Care plan alignment.
Silence invites inference. Structured documentation transforms predictive visibility into reliability evidence.
Centers for Medicare & Medicaid Services Regulatory Overlay: Admissibility Meets Compliance
Facilities participating in Medicare and Medicaid must comply with 42 C.F.R. Part 483,[10] including:
- Quality of care standards;[11]
- Comprehensive assessment and care planning;[12]
- Infection prevention and control;[13]
- Quality Assurance and Performance Improvement requirements;[14]
- Staffing sufficiency mandates.[15]
Predictive systems intersect directly with these domains. Failure to reconcile predictive alerts may create both litigation exposure and survey risk. Conversely, structured reconciliation may demonstrate proactive compliance. Admissibility and regulatory posture are increasingly intertwined.
Governance Visibility and Enterprise Risk
Predictive analytics elevate scrutiny beyond bedside care to enterprise oversight. Litigation inquiry may extend to whether:
- Escalation protocols were defined;
- Dashboards were reviewed;
- Vendor updates were evaluated;
- Staff were trained on advisory function.
Corporate oversight jurisprudence has long recognized that reporting systems require active monitoring.[16] Predictive dashboards function as modern reporting systems. Visibility without governance creates systemic narrative risk. Visible oversight stabilizes institutional posture.
Conclusion
AI does not redefine the standard of care in long term care. It redefines visibility. Visibility generates discoverable artifacts. Discoverable artifacts generate scrutiny. Scrutiny generates narrative risk.
The admissibility question in AI-influenced litigation is not whether predictive analytics are sophisticated. It is whether their outputs were governed, reconciled, and documented with disciplined reasoning consistent with reasonable care.
When alerts are contextualized within chronology, reassessment, and clinical judgment, AI becomes advisory evidence. When alerts are unexplained, ignored, or overstated, AI becomes adversarial evidence.
For health care litigators and compliance leaders, the strategic imperative is clear: governance architecture and documentation discipline determine whether predictive visibility amplifies exposure or reinforces defensibility. Structure determines liability.
About the Author
Michelle Carroll is the Founder & Chief Clinical Strategist of Lexcura Summit Medical-Legal Consulting. With four decades of experience across hospital acute care, home health, hospice, and long-term care, she brings extensive clinical and operational expertise to complex healthcare litigation. She is the architect of the Lexcura Clinical Intelligence Model™, a structured framework for analyzing medical records and evaluating standard of care, regulatory exposure, and causation. Her work supports both plaintiff and defense counsel in developing clear, defensible clinical strategy in high-stakes cases.
Endnotes
[1] Restatement (Second) of Torts § 283 (Am. L. Inst. 1965).
[2] Fed. R. Evid. 702(a)–(d).
[3] 509 U.S. 579 (1993).
[4] 526 U.S. 137 (1999).
[5] See Daubert, 509 U.S. at 595.
[6] 522 U.S. 136, 146 (1997).
[7] Id. at 593–94.
[8] 293 F. 1013 (D.C. Cir. 1923).
[9] Restatement (Second) of Torts § 283.
[10] 42 C.F.R. pt. 483 (2024).
[11] 42 C.F.R. § 483.25.
[12] 42 C.F.R. § 483.21.
[13] 42 C.F.R. § 483.80.
[14] 42 C.F.R. § 483.75.
[15] 42 C.F.R. § 483.35.
[16] In re Caremark Int'l Inc. Derivative Litig., 698 A.2d 959 (Del. Ch. 1996).
Copyright 2026, American Health Law Association, Washington, DC. Reprint permission granted.
Michelle Carroll is the Founder and Chief Clinical Strategist of Lexcura Summit, where she leads clinical intelligence reviews of medical records for attorneys and healthcare organizations.
Talk to Us
If AI-generated alerts sit in your record, we can help you assess what they show, what was done with them, and how they will read to a court. Visit lexcurasummit.com or book a brief conversation at calendly.com/michelle-lexcurasummit.